{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:26:37Z","timestamp":1790735197252,"version":"4.1.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1007\/s11938-003-0010-0","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T18:13:45Z","timestamp":1180894425000},"page":"93-103","source":"Crossref","is-referenced-by-count":10,"title":["Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis"],"prefix":"10.1007","volume":"6","author":[{"given":"Cynthia","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Lindor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10_CR1","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1053\/gast.2000.20197","volume":"119","author":"WR Kim","year":"2000","unstructured":"Kim WR, Lindor KD, Locke GR 3rd, et al.: Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000, 119:1631\u20131636. The first population-based study in the United States evaluating incidence and prevalence of PBC.","journal-title":"Gastroenterology"},{"key":"10_CR2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/s-2002-34506","volume":"22","author":"A Nishio","year":"2002","unstructured":"Nishio A, Keeffe EB, Gershwin ME: Immunopathogenesis of primary biliary cirrhosis. Semin Liver Dis 2002, 22:291\u2013302.","journal-title":"Semin Liver Dis"},{"key":"10_CR3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hep.510250103","volume":"25","author":"MD Norstrand Van","year":"1997","unstructured":"Van Norstrand MD, Malinchoc M, Lindor KD, et al.: Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 1997, 25:6\u201311.","journal-title":"Hepatology"},{"key":"10_CR4","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1572-0241.2002.05620.x","volume":"97","author":"S Joshi","year":"2002","unstructured":"Joshi S, Cauch-Dudeck K, Heathcote EJ, et al.: Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterol 2002, 97:999\u20131002.","journal-title":"Am J Gastroenterol"},{"key":"10_CR5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.1840120116","volume":"12","author":"H Witt-Sullivan","year":"1990","unstructured":"Witt-Sullivan H, Heathcote J, Cauch K, et al.: The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990, 12:98\u2013105.","journal-title":"Hepatology"},{"key":"10_CR6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","volume":"123","author":"M Prince","year":"2002","unstructured":"Prince M, Chetwynd A, Newman W, et al.: Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002, 123:1044\u20131051.","journal-title":"Gastroenterology"},{"key":"10_CR7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/jhep.2001.21165","volume":"33","author":"A Parikh-Patel","year":"2001","unstructured":"Parikh-Patel A, Gold EB, Worman H, et al.: Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology 2001, 33:16\u201321.","journal-title":"Hepatology"},{"key":"10_CR8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/00042737-199906000-00007","volume":"11","author":"E Jones","year":"1999","unstructured":"Jones E, Bergasa N: The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur J Gastroenterol Hepatol 1999, 11:623\u2013631.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10_CR9","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1111\/j.1572-0241.2001.04134.x","volume":"96","author":"J Phillips","year":"2001","unstructured":"Phillips J, Angulo P, Petterson T, Lindor KD: Fatsoluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001, 96:2745\u20132750.","journal-title":"Am J Gastroenterol"},{"key":"10_CR10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0168-8278(01)00144-1","volume":"35","author":"K Menon","year":"2001","unstructured":"Menon K, Angulo P, Weston S, et al.: Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001, 35:316\u2013323. This study confirmed the higher prevalence of bone disease among patients with PBC and identified risk factors for the development of severe osteoporosis.","journal-title":"J Hepatol"},{"key":"10_CR11","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1172\/JCI117959","volume":"95","author":"CH Janes","year":"1995","unstructured":"Janes CH, Dickson ER, Okazaki R, et al.: Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995, 95:2581\u20132586.","journal-title":"J Clin Invest"},{"key":"10_CR12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/jhep.2002.36357","volume":"36","author":"MM Guichelaar","year":"2002","unstructured":"Guichelaar MM, Malinchoc M, Sibonga J, et al.: Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology 2002, 36:895\u2013903.","journal-title":"Hepatology"},{"key":"10_CR13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","volume":"35","author":"KN Lazaridis","year":"2001","unstructured":"Lazaridis KN, Gores GJ, Lindor KD: Ursodeoxycholic acid \u2018mechanisms of action and clinical use in hepatobiliary disorders\u2019. J Hepatol 2001, 35:134\u201346.","journal-title":"J Hepatol"},{"key":"10_CR14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","volume":"36","author":"G Paumgartner","year":"2002","unstructured":"Paumgartner G, Beuers U: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002, 36:525\u2013531.","journal-title":"Hepatology"},{"key":"10_CR15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","volume":"1","author":"R Poupon","year":"1987","unstructured":"Poupon R, Chretien Y, Poupon RE, et al.: Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis. Lancet 1987, 1:834\u2013836.","journal-title":"Lancet"},{"key":"10_CR16","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","volume":"324","author":"R Poupon","year":"1991","unstructured":"Poupon R, Balkau B, Eschwege E, Poupon R: A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis -UDCA-PBC Study Group. N Engl J Med 1991, 324:1548\u20131554.","journal-title":"N Engl J Med"},{"key":"10_CR17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","volume":"19","author":"EJ Heathcote","year":"1994","unstructured":"Heathcote EJ, Cauch-Dudek K, Walker V, et al.: The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994, 19:1149\u20131156.","journal-title":"Hepatology"},{"key":"10_CR18","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","volume":"106","author":"K Lindor","year":"1994","unstructured":"Lindor K, Dickson ER, Baldus WP, et al.: Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994, 106:1284\u20131290.","journal-title":"Gastroenterology"},{"key":"10_CR19","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0016-5085(89)91698-3","volume":"97","author":"U Leuschner","year":"1989","unstructured":"Leuschner U, Fischer H, Kurtz W, et al.: Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989, 97:1268\u20131274.","journal-title":"Gastroenterology"},{"key":"10_CR20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1440-1746.1994.tb01237.x","volume":"9","author":"IB Turner","year":"1994","unstructured":"Turner IB, Myszor M, Mitchison HC, et al.: A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol 1994, 9:162\u2013168.","journal-title":"J Gastroenterol Hepatol"},{"key":"10_CR21","first-page":"759","volume":"22","author":"B Combes","year":"1995","unstructured":"Combes B, Carithers RL Jr, Maddrey WC, et al.: A randomized, double-blind, placebo controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22:759\u2013766.","journal-title":"Hepatology"},{"key":"10_CR22","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","volume":"113","author":"R Poupon","year":"1997","unstructured":"Poupon R, Lindor KD, Cauch-Dudeck, et al.: Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113:884\u2013890. First combined analysis of clinical trials assessing efficacy of UDCA in PBC. Established that UDCA therapy improves survival free of liver transplantation in patients with advanced stage of disease.","journal-title":"Gastroenterology"},{"key":"10_CR23","first-page":"354","volume":"XX","author":"J Goulis","year":"1999","unstructured":"Goulis J, Leandro G, Burroughs A: Randomised controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: a meta-analyis. Lancet 1999, XX:354.","journal-title":"Lancet"},{"key":"10_CR24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0168-8278(00)80232-9","volume":"32","author":"R Poupon","year":"2000","unstructured":"Poupon R: Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past\u2014issues for the future. J Hepatol 2000, 32:685\u2013688.","journal-title":"J Hepatol"},{"key":"10_CR25","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","volume":"29","author":"P Angulo","year":"1999","unstructured":"Angulo P, Batts KP, Therneau TM, et al.: Long term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999, 29:644\u2013647.","journal-title":"Hepatology"},{"key":"10_CR26","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","volume":"32","author":"C Corpechot","year":"2000","unstructured":"Corpechot C, Carrat F, Bonnand AM, et al.: The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000, 32:1196\u20131199.","journal-title":"Hepatology"},{"key":"10_CR27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","volume":"32","author":"A Pares","year":"2000","unstructured":"Pares A, Caballeria L, Rodes J, et al.: Long term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. J Hepatol 2000, 32:561\u2013566.","journal-title":"J Hepatol"},{"key":"10_CR28","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4065\/72.12.1137","volume":"72","author":"K Lindor","year":"1997","unstructured":"Lindor K, Jorgensen RA, Therneau TM, et al.: Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997, 72:1137\u20131140.","journal-title":"Mayo Clin Proc"},{"key":"10_CR29","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0025-6196(12)61815-1","volume":"69","author":"V Balan","year":"1994","unstructured":"Balan V, Dickson ER, Jorgensen RA, Lindor KD: Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. Mayo Clin Proc 1994, 69:923\u2013929.","journal-title":"Mayo Clin Proc"},{"key":"10_CR30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","volume":"19","author":"P Angulo","year":"1999","unstructured":"Angulo P, Lindor KD, Therneau TM, et al.: Utilization of the Mayo Risk Score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999, 19:115\u2013121. This study clearly indicated that the Mayo Risk Score could continue being used as a prognostic index in patients with PBC who are treated with UDCA. The study also identified serum alkaline phosphatase as a reliable marker to assess response to therapy.","journal-title":"Liver"},{"key":"10_CR31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/gut.46.1.121","volume":"46","author":"M Leuschner","year":"2000","unstructured":"Leuschner M, Dietrich CF, You T, et al.: Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut 2000, 46:121\u2013126.","journal-title":"Gut"},{"key":"10_CR32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0168-8278(96)80327-8","volume":"25","author":"M Leuschner","year":"1996","unstructured":"Leuschner M, Guldutuna S, You T, et al.: Ursodeoxycholic acid and prednisolone versus ursodeoxycholic and placebo in the treatment of primary biliary cirrhosis. J Hepatol 1996, 25:49\u201357.","journal-title":"J Hepatol"},{"key":"10_CR33","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","volume":"117","author":"M Leuschner","year":"1999","unstructured":"Leuschner M, Maier KP Schlichting J, et al.: Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999, 117:918\u2013925.","journal-title":"Gastroenterology"},{"key":"10_CR34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","volume":"31","author":"P Angulo","year":"2000","unstructured":"Angulo P, Jorgensen RA, Keach JC, et al.: Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000, 31:318\u2013323.","journal-title":"Hepatology"},{"key":"10_CR35","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0168-8278(98)80254-7","volume":"29","author":"FH Wolfhagen","year":"1998","unstructured":"Wolfhagen FH, van Hoogstraten HJ, van Buuren HR, et al.: Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J Hepatol 1998, 29:736\u2013742.","journal-title":"J Hepatol"},{"key":"10_CR36","first-page":"1165","volume":"11","author":"E Jones","year":"1999","unstructured":"Jones E, ten Cate FJ, ter Berg, et al.: Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999, 11:1165\u20131169.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10_CR37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0168-8278(05)80004-2","volume":"18","author":"H Buscher","year":"1993","unstructured":"Buscher H, Zietzschmann Y, Gerok W: Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid. J Hepatol 1993, 18:9\u201314.","journal-title":"J Hepatol"},{"key":"10_CR38","first-page":"1158","volume":"22","author":"K Lindor","year":"1995","unstructured":"Lindor K, Dickson ER, Jorgensen RA, et al.: The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology 1995, 22:1158\u20131162.","journal-title":"Hepatology"},{"key":"10_CR39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-8278(97)80294-2","volume":"27","author":"A Gonzalez-Koch","year":"1997","unstructured":"Gonzalez-Koch A, Brahm J, Antezana C, et al.: The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol 1997, 27:143\u2013149.","journal-title":"J Hepatol"},{"key":"10_CR40","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/gast.1999.0029900395","volume":"117","author":"Bonis","year":"1999","unstructured":"Bonis, P, Kaplan M: Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol. Gastroenterology 1999, 117:395\u2013399.","journal-title":"Gastroenterology"},{"key":"10_CR41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0168-8278(96)80191-7","volume":"24","author":"T Ikeda","year":"1996","unstructured":"Ikeda T, Tozuka S, Noguchi O, et al.: Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study. J Hepatol 1996, 24:88\u201394.","journal-title":"J Hepatol"},{"key":"10_CR42","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/hep.510240520","volume":"24","author":"R Poupon","year":"1996","unstructured":"Poupon R, Huet PM, Poupon R, et al.: A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1996, 24:1098\u20131103.","journal-title":"Hepatology"},{"key":"10_CR43","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1046\/j.1365-2036.2001.01018.x","volume":"15","author":"P Battezzati","year":"2001","unstructured":"Battezzati P, Zuin M, Crosignani A, et al.: Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Aliment Pharmacol Ther 2001, 15:1427\u20131434.","journal-title":"Aliment Pharmacol Ther"},{"key":"10_CR44","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/jhep.2000.18663","volume":"32","author":"P Angulo","year":"2000","unstructured":"Angulo P, Patel T Jorgensen RA, et al.: Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000, 32:897\u2013900.","journal-title":"Hepatology"},{"key":"10_CR45","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","volume":"95","author":"T Kurihara","year":"2000","unstructured":"Kurihara T, Niimi A, Maeda A, et al.: Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 2000, 95:2990\u20132992.","journal-title":"Am J Gastroenterol"},{"key":"10_CR46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1572-0241.2002.05413.x","volume":"97","author":"T Kurihara","year":"2002","unstructured":"Kurihara T, Maeda A, Shigemoto M, et al.: Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol 2002, 97:212\u2013214.","journal-title":"Am J Gastroenterol"},{"key":"10_CR47","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","volume":"95","author":"S Nakai","year":"2000","unstructured":"Nakai S, Masaki T, Kurokohchi K, et al.: Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000, 95:326\u2013327.","journal-title":"Am J Gastroenterol"},{"key":"10_CR48","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0016-5085(19)33896-X","volume":"57","author":"F Schaffner","year":"1965","unstructured":"Schaffner F: Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis. Gastroenterology 1965, 57:253\u2013255.","journal-title":"Gastroenterology"},{"key":"10_CR49","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0016-5085(19)32419-9","volume":"69","author":"JA Summerfield","year":"1975","unstructured":"Summerfield JA, Elias E, Sherlock S: Effects of clofibrate in primary biliary cirrhosis hypercholesterolemia and gallstones. Gastroenterology 1975, 69:998\u20131000.","journal-title":"Gastroenterology"},{"key":"10_CR50","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0168-8278(02)00006-5","volume":"36","author":"U Ritzel","year":"2002","unstructured":"Ritzel U, Leonhardt U, Nather M, et al.: Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002, 36:454\u2013458.","journal-title":"J Hepatol"},{"key":"10_CR51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s005340050128","volume":"6","author":"K Menon","year":"1999","unstructured":"Menon K, Wiesner R: Etiology and natural history of primary sclerosing cholangitis. J Hepatobiliary Pancreatic Surg 1999, 6:343\u2013351.","journal-title":"J Hepatobiliary Pancreatic Surg"},{"key":"10_CR52","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJM199504063321406","volume":"332","author":"YM Lee","year":"1995","unstructured":"Lee YM, Kaplan MM: Primary sclerosing cholangitis. N Engl J Med 1995, 332:924\u2013933.","journal-title":"N Engl J Med"},{"key":"10_CR53","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.1840100406","volume":"10","author":"RH Wiesner","year":"1989","unstructured":"Wiesner RH, Grambsch PM, Dickson ER, et al.: Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989, 10:430\u2013436.","journal-title":"Hepatology"},{"key":"10_CR54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00000658-199101000-00004","volume":"213","author":"CB Rosen","year":"1991","unstructured":"Rosen CB, Nagorney DM, Wiesner RH, et al.: Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991, 213:21\u201325.","journal-title":"Ann Surg"},{"key":"10_CR55","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/0016-5085(91)90673-9","volume":"100","author":"JM Farrant","year":"1991","unstructured":"Farrant JM, Hayllar KM, Wilkinson ML, et al.: Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991, 100:1710\u20131717.","journal-title":"Gastroenterology"},{"key":"10_CR56","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/gut.38.4.610","volume":"38","author":"U Broome","year":"1996","unstructured":"Broome U, Olsson R, Loof L, et al.: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38:610\u2013615.","journal-title":"Gut"},{"key":"10_CR57","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0039-6060(05)80078-9","volume":"117","author":"O Farges","year":"1995","unstructured":"Farges O, Malassagne B, Sebagh M Bismuth H: Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 1995, 117:146\u2013155.","journal-title":"Surgery"},{"key":"10_CR58","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","volume":"36","author":"A Bergquist","year":"2002","unstructured":"Bergquist A, Ekbom A, Olsson R, et al.: Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36:321\u2013327. Very interesting population-based study with a large cohort of PSC patients that confirmed the higher prevalence of cholangiocarcinoma in patients with PSC and highlighted an increased prevalence of other hepatic and extrahepatic malignancies, such as pancreatic and colon cancers.","journal-title":"J Hepatol"},{"key":"10_CR59","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00004836-199504000-00011","volume":"20","author":"RA Jorgensen","year":"1995","unstructured":"Jorgensen RA, Lindor KD, Sartin JS, et al.: Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol 1995, 20:215\u2013219.","journal-title":"J Clin Gastroenterol"},{"key":"10_CR60","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0168-8278(98)80253-5","volume":"29","author":"P Angulo","year":"1998","unstructured":"Angulo P, Therneau TM, Jorgensen A, et al.: Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 1998, 29:729\u2013735.","journal-title":"J Hepatol"},{"key":"10_CR61","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1572-0241.2001.03777.x","volume":"96","author":"DM Harnois","year":"2001","unstructured":"Harnois DM, Angulo P, Jorgensen RA, et al.: High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1558\u20131562.","journal-title":"Am J Gastroenterol"},{"key":"10_CR62","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.27965","volume":"121","author":"SA Mitchell","year":"2001","unstructured":"Mitchell SA, Bansi DS, Hunt N, et al.: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900\u2013907. Well-conducted trial suggesting that high-dose UDCA could be an effective therapy for patients with PSC, setting the stage for larger trials that are currently under evaluation.","journal-title":"Gastroenterology"},{"key":"10_CR63","first-page":"455","volume":"90","author":"DH Thiel Van","year":"1995","unstructured":"Van Thiel DH, Carrol P, Abu-Elmagd K, et al.: Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995, 90:455\u2013459.","journal-title":"Am J Gastroenterol"},{"key":"10_CR64","first-page":"661","volume":"21","author":"JG Lee","year":"1995","unstructured":"Lee JG, Schutz SM, England RE, et al.: Endoscopic therapy of sclerosing cholangitis. Hepatology 1995, 21:661\u2013667.","journal-title":"Hepatology"},{"key":"10_CR65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0016-5107(96)70167-0","volume":"44","author":"AW Milligen de Wit van","year":"1996","unstructured":"van Milligen de Wit AW, van Bracht J, Fauws EA, et al.: Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1996, 44:293\u2013299.","journal-title":"Gastrointest Endosc"},{"key":"10_CR66","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0168-8278(97)80421-7","volume":"26","author":"A Stiehl","year":"1997","unstructured":"Stiehl A, Rudolph G, Sauer P, et al.: Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997, 26:560\u2013566.","journal-title":"J Hepatol"},{"key":"10_CR67","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0016-5107(01)70403-8","volume":"53","author":"AR Baluyut","year":"2001","unstructured":"Baluyut AR, Sherman S, Lehman GA, et al.: Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001, 53:308\u2013312.","journal-title":"Gastrointest Endosc"},{"key":"10_CR68","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0168-8278(05)80467-2","volume":"20","author":"A Stiehl","year":"1994","unstructured":"Stiehl A, Walker S, Stiehl L, et al.: Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994, 20:57\u201364.","journal-title":"J Hepatol"},{"key":"10_CR69","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s005340050132","volume":"6","author":"SA Ahrendt","year":"1999","unstructured":"Ahrendt SA, Pitt HA: Surgical treatment for primary sclerosing cholangitis. J Hepatobiliary Pancreat Surg 1999, 6:366\u2013372.","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"10_CR70","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/hep.510230526","volume":"23","author":"B Nashan","year":"1996","unstructured":"Nashan B, Schlitt HJ, Tusch G, et al.: Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation. Hepatology 1996, 23:1105\u20131111.","journal-title":"Hepatology"},{"key":"10_CR71","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","volume":"30","author":"P Angulo","year":"1999","unstructured":"Angulo P, Dickson ER, Therneau TM, et al.: Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999, 30:830\u2013835.","journal-title":"J Hepatol"},{"key":"10_CR72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/hep.510290116","volume":"29","author":"T Pasha","year":"1999","unstructured":"Pasha T, Heathcote J, Gabriel S, et al.: Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999, 29:21\u201326.","journal-title":"Hepatology"},{"key":"10_CR73","unstructured":"Drug Topics Red Book. Montvale, NJ: Medical Economics Co; 2002."},{"key":"10_CR74","first-page":"387","volume":"48","author":"S Linder","year":"2001","unstructured":"Linder S, Soderlund C: Endoscopic therapy in primary sclerosing cholangitis: outcome of treatment and risk of cancer. Hepatogastroenterology 2001, 48:387\u2013392.","journal-title":"Hepatogastroenterology"},{"key":"10_CR75","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/bjs.1800780515","volume":"78","author":"T Ismail","year":"1991","unstructured":"Ismail T, Agrisani L, Powell JE, et al.: Primary sclerosing cholangitis: surgical options, prognostic variables and outcome. Br J Surg 1991, 78:564\u2013567.","journal-title":"Br J Surg"},{"key":"10_CR76","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00042737-200111000-00022","volume":"13","author":"J Neuberger","year":"2001","unstructured":"Neuberger J, Jones E: Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol 2001, 13:393\u2013394.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10_CR77","first-page":"S9","volume":"4","author":"JE Hay","year":"1998","unstructured":"Hay JE: Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection? Liver Transpl Surg 1998, 4:S9-S17.","journal-title":"Liver Transpl Surg"},{"key":"10_CR78","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hep.510300501","volume":"30","author":"IW Graziadei","year":"1999","unstructured":"Graziadei IW, Wiesner RH, Marotta PJ, et al.: Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999, 30:1121\u20131127.","journal-title":"Hepatology"},{"key":"10_CR79","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1053\/jlts.2002.33952","volume":"8","author":"IW Graziadei","year":"2002","unstructured":"Graziadei IW: Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2002, 8:575\u2013681.","journal-title":"Liver Transpl"},{"key":"10_CR80","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)72401-6","volume":"355","author":"K Lindor","year":"2000","unstructured":"Lindor K, Poupon R, Poupon R, et al.: Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000, 355:657\u2013658.","journal-title":"Lancet"},{"key":"10_CR81","first-page":"253A","volume":"34","author":"S Cauduro","year":"2001","unstructured":"Cauduro S, Wiesner RH, Brandhagen DJ, et al.: Long term results of patients undergoing liver transplantation for primary biliary cirrhosis at a single center. Hepatology 2001, 34:253A.","journal-title":"Hepatology"},{"key":"10_CR82","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/lt.500050419","volume":"5","author":"E Heathcote","year":"1999","unstructured":"Heathcote E, Stone J, Cauch-Dudek K, et al.: Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Liver Transplant Surg 1999, 5:269\u2013274.","journal-title":"Liver Transplant Surg"},{"key":"10_CR83","doi-asserted-by":"crossref","first-page":"472A","DOI":"10.1016\/S0168-8278(99)80107-X","volume":"30","author":"A Pares","year":"1999","unstructured":"Pares A, Guanabens N, Ros I, et al.: Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis [abstract]. Hepatology 1999. 30:472A.","journal-title":"Hepatology"},{"key":"10_CR84","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","volume":"337","author":"PD Bjarnason NH Delmas","year":"1997","unstructured":"Delmas PD Bjarnason NH, Mitlak BH, et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337:1641\u20131647.","journal-title":"N Engl J Med"},{"key":"10_CR85","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0168-8278(01)00133-7","volume":"35","author":"S Nishiguchi","year":"2001","unstructured":"Nishiguchi S, Shimoi S, Kurooka H, et al.: Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. J Hepatol 2001, 35:543\u2013555.","journal-title":"J Hepatol"},{"key":"10_CR86","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0304-3959(94)00145-5","volume":"61","author":"H Schworer","year":"1995","unstructured":"Schworer H, Hartmann H, Ramadori G: Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995, 61:33\u201337.","journal-title":"Pain"},{"key":"10_CR87","first-page":"455","volume":"27","author":"Martino M Di","year":"1995","unstructured":"Di Martino M, Galanti B, Nardiello S: Treatment of cholestatic itching in primary biliary cirrhosis with ondansetron. Ital J Gastroenterol 1995, 27:455.","journal-title":"Ital J Gastroenterol"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-003-0010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-003-0010-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-003-0010-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T17:50:33Z","timestamp":1587577833000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-003-0010-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s11938-003-0010-0","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4]]}}}